Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer.
暂无分享,去创建一个
N. Kohno | K. Hiwada | A. Yokoyama | K Hiwada | K. Kondo | Y. Hirasawa | Y Hirasawa | N Kohno | A Yokoyama | K Kondo | M Miyake | M. Miyake | Akihito Yokoyama | Nobuoki Kohno | Kunio Hiwada | Masayuki Miyake
[1] L. Frati,et al. Human B-cell immune response to the polymorphic epithelial mucin. , 1993, Cancer research.
[2] S. Hakomori,et al. Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. , 1992, The New England journal of medicine.
[3] H. Satoh,et al. Predictive value of preoperative serum sialyl Lewis X-i antigen levels in non-small cell lung cancer. , 1998, Anticancer research.
[4] N. Kohno,et al. KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. , 1997, American journal of respiratory cell and molecular biology.
[5] C. Angeletti,et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] R. Dahiya,et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. , 1993, Cancer research.
[7] T. Kipps,et al. Structure-function studies on a polyreactive (natural) autoantibody. Polyreactivity is dependent on somatically generated sequences in the third complementarity-determining region of the antibody heavy chain. , 1994, Journal of immunology.
[8] M. Reddish,et al. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 , 1998, Nature Medicine.
[9] P. Kenemans,et al. Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. , 1995, British Journal of Cancer.
[10] N. Kohno,et al. Detection of a circulating tumor-associated antigen with a murine monoclonal antibody, LISA 101, selected by reversed indirect enzyme-linked immunosorbent assay. , 1989, Cancer research.
[11] R. Metzgar,et al. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. , 1994, Cancer research.
[12] N. Peat,et al. Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. , 1992, Cancer research.
[13] S. Avrameas,et al. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. , 1991, Immunology today.
[14] W. Gilks,et al. Third international workshop on lung tumor and differentiation antigens: Overview of the results of the central data analysis , 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.
[15] N. Kohno,et al. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. , 1998, Cancer research.
[16] N. Kohno,et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. , 1989, Chest.
[17] G. Catalano,et al. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. , 1998, Oncology reports.
[18] H. Stein,et al. Carbohydrate Recognition on MUC1‐Expressing Targets Enhances Cytotoxicity of a T Cell Subpopulation , 1997, Scandinavian journal of immunology.
[19] V. Apostolopoulos,et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. , 1997, The Journal of clinical investigation.
[20] N. Kohno,et al. A New Serum Tumor Marker, CAM 123‐6, Highly Specific to Pulmonary Adenocarcinoma , 1994, Japanese journal of cancer research : Gann.
[21] M. McGuckin,et al. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women , 1998, Cancer Immunology, Immunotherapy.
[22] J. Bártková,et al. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM‐3 is selectively exposed in a range of primary carcinomas , 1989, International journal of cancer.
[23] S. Meijer,et al. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. , 1996, European journal of cancer.
[24] O. Nilsson,et al. Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies against the MUC1 Mucin , 1997, Tumor Biology.
[25] M. Reddish,et al. Anti‐MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide , 1998, International journal of cancer.
[26] A. Harris,et al. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. , 1998, Journal of clinical pathology.
[27] I. Cohen,et al. Autoimmunity, microbial immunity and the immunological homunculus. , 1991, Immunology today.
[28] N. Kohno,et al. Difference in sero‐diagnostic values among KL‐6‐associated mucins classified as cluster 9 , 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.
[29] J. Taylor‐Papadimitriou,et al. Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[30] W. Bodmer,et al. Monoclonal antibodies to epithelium‐specific components of the human milk fat globule membrane: Production and reaction with cells in culture , 1981, International journal of cancer.
[31] M. Volm,et al. Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. , 1997, British Journal of Cancer.
[32] N. Kohno,et al. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. , 1988, Japanese journal of clinical oncology.
[33] N. Kohno,et al. Immunoreactive MUC1 Expression at the Deepest Invasive Portion Correlates with Prognosis of Colorectal Cancer , 1998, Oncology.